Who Paid My Doc
Miten Vasa
Rheumatology Fontana, CA Medical Doctor
NPI 1972769792 CMS profile 1159960
9961 Sierra Ave, Kaiser Permanente, Department Of Internal Medicine, Fontana, CA 92335
General payments
$121
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Miten Vasa of Fontana, CA is reported in the CMS Open Payments database as having received $121 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 13th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $121 | 1 |
Beside peers
- Miten Vasa
- Rheumatology median
- Middle half of Rheumatology
- National median
In program year 2025, general payments to Miten Vasa were reported at $0. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.
Show as a table
| Year | Miten Vasa | Rheumatology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $744 | $153–$2,687 | $163 |
| 2020 | $0 | $462 | $98–$2,027 | $114 |
| 2021 | $0 | $531 | $101–$2,153 | $132 |
| 2022 | $0 | $627 | $125–$2,303 | $149 |
| 2023 | $121 | $741 | $145–$2,524 | $160 |
| 2024 | $0 | $830 | $166–$2,660 | $164 |
| 2025 | $0 | $903 | $171–$2,775 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 56 drugsPart D claims
3,892
Drug cost
$2,817,684
Branded share of claims
42.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Enbrel Sureclick Etanercept | Brand | 127 | $619,218 | |
| Rinvoq Upadacitinib | Brand | 85 | $450,389 | |
| Amjevita(Cf) Autoinjector Adalimumab-Atto | Brand | 167 | $309,341 | |
| Humira(Cf) Pen Adalimumab | Brand | 27 | $239,523 | |
| Orencia Clickject Abatacept | Brand | 42 | $192,902 | |
| Xeljanz Tofacitinib Citrate | Brand | 64 | $159,482 | |
| Benlysta Belimumab | Brand | 29 | $153,062 | |
| Otezla Apremilast | Brand | 32 | $141,122 | |
| Simponi Golimumab | Brand | 20 | $116,397 | |
| Rasuvo Methotrexate/Pf | Brand | 153 | $114,126 |
The 10 drugs with the highest cost, of 56 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Rheumatology in California
Related records
Rheumatology in California
Practitioners in the same specialty and state, ranked by reported value.
All Rheumatology
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.